JB Chemicals & Pharmaceuticals Ltd Stock Analysis

BSE: 506943 | NSE: JBCHEPHARM | Pharmaceuticals & Drugs | Mid Cap

BSE Share Price 06-Dec-2022 18:01
2029.25 9.80 (0.49%)

DeciZen - Make an Informed Decision on JB Chem & Pharma

Overall Rating

1. Quality

2. Valuation

Overvalued

3. Price Trend

JB Chem & Pharma Price Chart

P/E Ratio (SA) :
44.06
Market Cap :
15,697.1 Cr.
52-wk low :
1,339.1
52-wk high :
2,149.9
Bole Toh?

1. Is JB Chemicals & Pharmaceuticals Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that JB Chemicals & Pharmaceuticals Ltd is a good quality company.

2. Is JB Chemicals & Pharmaceuticals Ltd undervalued or overvalued?

The key valuation ratios of JB Chemicals & Pharmaceuticals Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.

3. Is JB Chemicals & Pharmaceuticals Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of JB Chemicals & Pharmaceuticals Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

10 Year X-Ray of JB Chem & Pharma:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
JB Chemicals & Pharmaceuticals Ltd has performed well in majority of the past ten years indicating its past ten year financial track record is very good

Value Creation

Value Creation Index Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
ROCE % 7.6%9.6%10.2%12.3%10.6%7.5%10.9%16.8%24.5%17.1%-
Value Creation Index -0.5-0.3-0.3-0.1-0.2-0.5-0.20.20.80.3-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 8169571,0611,1651,1991,2551,5011,6411,8922,1902,573
YoY Gr. Rt. %-17.2%11%9.8%2.9%4.7%19.6%9.3%15.3%15.7%-
Adj EPS 8.9121317.417.312.719.932.251.843.346.1
YoY Gr. Rt. %-34.7%8.8%33.5%-0.4%-26.5%56.5%61.7%60.9%-16.4%-
BVPS (₹) 119.1123.7119.8144.2163.6173.9185187233.8264.1294.1
Adj Net Profit 75.3101110147147106160249401335356
Cash Flow from Ops. 80.4-11.7143171178116193272335147-
Debt/CF from Ops. 0.6-80.710.30.30.10.10.10.2-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 11.6%12.8%13.4%15.7%
Adj EPS 19.3%20.1%29.6%-16.4%
BVPS 9.310.112.613
Share Price 37.3% 47.3% 71.4% 28.3%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'13Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22TTM
Return on Equity % 7.79.910.713.211.37.510.91724.617.116.5
Op. Profit Mgn % 14.816.218.619.61915.919.522.629.223.222.1
Net Profit Mgn % 9.210.610.412.712.38.510.615.221.215.313.9
Debt to Equity 0.10.10.10.10000000.1
Working Cap Days 162161162214276290269224191225172
Cash Conv. Cycle 879710095969887817587107

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 13.41%

Net Profit is growing at healthy rate in last 3 years 29.58%

Sales growth is good in last 4 quarters at 24.30%

Return on Equity has declined versus last 3 years average to 16.50%

Latest Financials - JB Chemicals & Pharmaceuticals Ltd.

Standalone Consolidated
TTM EPS (₹) 46.1 49.8
TTM Sales (₹ Cr.) 2,573 2,819
BVPS (₹.) 294.1 299.3
Reserves (₹ Cr.) 2,259 2,300
P/BV 6.90 6.80
PE 44.06 40.90
From the Market
52 Week Low / High (₹) 1339.05 / 2149.90
All Time Low / High (₹) 5.41 / 2149.90
Market Cap (₹ Cr.) 15,697
Equity (₹ Cr.) 15.5
Face Value (₹) 2
Industry PE 37.5

Management X-Ray of JB Chem & Pharma :

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of JB Chem & Pharma

Adj EPS (Rs.)
Sales (Cr.)
ROE (%)
ROCE (%)

News

JB Chemicals & Pharmaceuticals Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of JB Chem & Pharma on 06-Dec-2022 18:01 is : 2,029.3.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 06-Dec-2022 18:01 the market cap of JB Chem & Pharma stood at ₹ 15,697.1.
The latest PE ratio of JB Chem & Pharma as of 06-Dec-2022 18:01 is 44.06.
The latest PB ratio of JB Chem & Pharma as of 06-Dec-2022 18:01 is 6.90
The 52-week high of JB Chem & Pharma is ₹ 2,149.9 and the 52-week low is ₹ 1,339.1.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue / sales of JB Chem & Pharma is ₹ 2,573 ( Cr.) .

About JB Chemicals & Pharmaceuticals Ltd

Established in 1976, J.B.Chemicals & Pharmaceuticals Ltd. (JBCPL) is one of India’s fastest growing pharmaceutical companies. An integrated, research-oriented, public listed organisation with a focus on supplying affordable, quality products both in India and International markets, JBCPL is trusted by healthcare professionals globally.

JBCPL is widely committed to manufacturing a range of innovative specialty products that include various pharmaceutical dosage forms like tablets, injectable (vials, ampoules, form fill seal), creams & ointments, lozenges, herbal liquids and capsules. In India and International markets, JBCPL is also known as Unique Pharmaceutical Laboratories and is a division of JBCPL.

JBCPL exports too many countries worldwide with presence in US, Europe, Australia, South Africa, other developing countries, Russia and CIS. The Company continues to invest in growing its share in the regulated markets such as USA, Europe and Australia. JBCPL has a strong R&D and regulatory set-up for development of new drug delivery system and formulations, filing of ANDAs and DMFs. Its state-of-the-art manufacturing facilities are approved by health authorities of key regulated markets.

Business area of the company

J. B. Chemicals & Pharmaceuticals is engaged in the business of manufacturing and marketing of diverse range of pharmaceutical formulations, herbal remedies and APIs.

Milestones & awards

1996-97

  • Shri. Dinesh Mody, Director, JBCPL, receiving the Prestigious National Export Award/Trophy for the year 1996-97, from the Hon’ble Prime Minister of India, Shri. Atal Behari Vajpayee

1999

  • J. B. Chemical & Pharmaceuticals Ltd. is honoured with the IDMA Quality Excellence Award: ‘Certificate of Merit’ for distinction in quality manufacturing at its manufacturing unit in Panoli.

2000

  • Company awarded a Golden Status certificate by the Govt. of India.

2001

  • J.B. Chemical & Pharmaceuticals Ltd. receives CHEMEXCIL’s ‘First Award’ for Outstanding Export Performance of Pharmaceuticals in the large-scale manufacturer’s category. Received South Africa MCA approval for its tablets facility at Panoli.

2003

  • First ANDA filing with USFDA for Ciprofloxacin.
  • First company to market Rantac CD.
  • Approval from Columbian Drug Regulatory Authority INVIMA for its state-of-the-art facility at Panoli.

2004

  • Features in the Forbes Global list 100 for “Best under $1 Billion” in Asia-Pacific.
  • Receives its maiden USFDA approval to market Ciprofloxacin tablets in the US market.
  • UKMHRA approves JBCPL’s tablet manufacturing facility at Panoli.

2005

  • TGA Australia approves JBCPL’s tablet manufacturing facilities at Panoli, Gujarat, India.
  • JBCPL receives USFDA approval to market Fluconazole tablets in the US market.
  • JBCPL features in Forbes Asia Pacific 200 List for “Best under a Billion” for second year in a row.

2006

  • The ‘Niryat Shree’ Certificate of Excellence was awarded to Unique Pharmaceutical Laboratories Limited, a division of JBCPL, by the Federation of Indian Export Organisations (FIEO) for outstanding export performance in the category of Chemicals, Drugs, Pharma & Allied Products, Non-SSI for the year 2004-05.

2007

  • JBCPL’s Annual Report for the year ended March 31, 2005 was awarded a merit certificate by the South Asian Federation of Accountants (SAFA), an apex body of SAARC, for the Best Presented Accounts for the year 2005 in the category of “Hospitality, Health, Transport, Shipping, etc.’

2008

  • Made a strategic investment in a company in South Africa called Biotech Laboratories.

2011

  • Divested the OTC portfolio in Russia, Ukraine and CIS to J&J.

2016

  •  Resignation of a director - Dr. Niranjan Maniar due to health problem.

2017

  • Shri J. B. Mody, Chairman, receives Lifetime Achievement Award.
  • Mr. J. B. Mody’s Lifetime Achievement Award AV on 13-11-2017.

2018

  • US FDA has approved Company's Abbreviated New Drug Application (ANDA) for Midodrine Hydrochloride Tablets USP 2.5 mg, 5 mg. and 10 mg. (for treatment of orthostatic hypotension).

2020

  • This is to inform you that US FDA has approved Company's Abbreviated New Drug Application (ANDA) for Carbamazepine Extended Release Tablets USP 100 mg, 200 mg and 400 mg.
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now